尤瑞克林联合阿托伐他汀钙治疗急性脑梗死的效果观察

Observation of therapeutic effect of urinary kallidinogenase combined with atorvastatin calcium on acute cerebral infarction

目的探究尤瑞克林联合阿托伐他汀钙治疗急性脑梗死(ACI)的效果。方法队列研究。抽取2022年1月至2023年12月南阳南石医院收治的ACI患者62例,按照随机数字表法分为对照组和研究组,每组31例。两组均采用常规治疗,对照组在常规治疗基础上使用阿托伐他汀钙,研究组在对照组基础上联用尤瑞克林。比较两组疗效,比较两组治疗前后炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-18(IL-18)、基质金属蛋白酶-9(MMP-9)]水平、美国国立卫生院卒中量表(NIHSS)评分、血管内皮功能[基质细胞衍生因子-1(SDF-1)、内皮素-1(ET-1)]及脑血流动力学指标。结果研究组总有效率(93.55%,29/31)高于对照组(70.97%,22/31),P<0.05;治疗后,研究组hs-CRP、IL-18、MMP-9水平低于对照组(P<0.05);治疗后,研究组NIHSS评分低于对照组(P<0.05);治疗后,研究组SDF-1高于对照组,ET-1低于对照组(P<0.05);治疗后,研究组外周阻力低于对照组,前动脉血流流速高于对照组(P<0.05)。结论尤瑞克林联合阿托伐他汀钙应用于ACI中,能减轻机体炎症,改善血管内皮功能和脑血流动力学指标,有效提升治疗效果。

Objective To investigate the effect of urinary kallidinogenase combined with atorvastatin calcium in the treatment of acute cerebral infarction(ACI).Methods A total of 62 ACI patients admitted to Nanshi Hospital of Nanyang from January 2022 to December 2023 were selected for the cohort study.And they were divided into a control group and a study group by random number table method,with 31 cases in each group.Both groups received conventional treatment;in addition,the control group received atorvastatin calcium for treatment,and the study group received urinary kallidinogenase combined with atorvastatin calcium for treatment.The therapeutic effect were compared between the two groups;the levels of inflammatory factors including high-sensitivity C-reactive protein(hs-CRP),interleukin-18(IL-18)and matrix metalloproteinase-9(MMP-9),National Institute of Health stroke scale(NIHSS)score,vascular endothelial function assessed by stromal cell-derived factor-1(SDF-1)and endothelin-1(ET-1),and cerebral hemodynamic indicators were compared between the two groups before and after treatment.Results The total effective rate of the study group(93.55%,29/31)was higher than that of the control group(70.97%,22/31),P<0.05.After treatment,the levels of hs-CRP,IL-18 and MMP-9 in the study group were lower than those in the control group(P<0.05).After treatment,the NIHSS score of the study group was lower than that of the control group(P<0.05).After treatment,the study group had higher SDF-1 level and lower ET-1 level compared with the control group(P<0.05).After treatment,the peripheral resistance of the study group was lower than that of the control group,and the blood flow velocity of the anterior artery was higher than that of the control group(P<0.05).Conclusions Urinary kallidinogenase combined with atorvastatin calcium in the treatment of ACI can reduce body inflammation,improve vascular endothelial function and cerebral hemodynamic indicators,and effectively promote the therapeutic effect.